Contract Research Organisation hVIVO plc (AIM: HVO), a company that specialises in human challenge clinical trials, on Wednesday announced positive results from a Phase 2a trial conducted for Shionogi & Co Ltd. The study evaluated the investigational oral RSV antiviral candidate S-337395, which holds Fast Track designation from the US FDA.
The randomised, placebo-controlled, double-blind trial, conducted using healthy volunteers recruited through FluCamp, demonstrated an 88.94% reduction in viral load at the highest dose (P
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab
Eneboparatide Shows Positive Results in Phase III Trial for Chronic Hypoparathyroidism
Precision BioSciences secures IND clearance for gene editing therapy targeting chronic hepatitis B
Xeris Biopharma secures FDA approval for Gvoke VialDx as diagnostic aid
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Korro Bio receives FDA orphan drug designation for KRRO-110
SpliceBio doses first patient in Phase 1/2 ASTRA study of SB-007
Amgen reports positive Phase 3 trial results for UPLIZNA in generalised myasthenia gravis
Femasys receives CE mark approval for FemBloc delivery system in Europe
European Commission approves Rxulti for adolescent schizophrenia treatment
Celltrion launches STELARA biosimilar STEQEYMA in US market
Hansa Biopharma completes enrolment for 20-HMedIdeS-19 PAES study